Albany Molecular Research Inc. (NASDAQ: AMRI) will replace Supertex Inc. (NASDAQ: SUPX) in the S&P SmallCap 600. Albany Molecular Research, Inc. (NASDAQ:AMRI) shares after opening at $17.90 moved to $18.69 on last trade day and at the end of the day closed at $18.36. Company price to sales ratio in past twelve months was calculated as 2.31 and price to cash ratio as 3.24. Albany Molecular Research, Inc. (NASDAQ:AMRI) showed a negative weekly performance of -7.79%.
Curis (NASDAQ:CRIS) had its price target reduced by Roth Capital from $10.00 to $9.00 in a research report sent to investors on Monday morning, AmericanBankingNews.com reports. Curis, Inc.(NASDAQ:CRIS) shares advanced 6.32% in last trading session and ended the day on $2.86. CRIS return on equity ratio is recorded as -33.10% and its return on assets is -17.00%. Curis, Inc.(NASDAQ:CRIS) yearly performance is -12.54%.
Oncolytics Biotech, Inc (NASDAQ:ONCY) announced that it has now entered into a share- purchase agreement with the Lincoln Park Capital Fund, LLC that will now provide the initial investment in Oncolytics of US$1.0M and make available the additional periodic-investments of upto US$25.0M over the 30-month term. Upon execution of this Purchase Agreement , Oncolytics Biotech, Inc (NASDAQ:ONCY) received the investment of US$1.0M in exchange for issuance of the 600,962 common-shares to LPC at the per-share purchase price of US$1.664. Apart from this, subject to terms & conditions of this Purchase Agreement, Oncolytics Biotech, Inc (NASDAQ:ONCY), at its sole discretion, might sell upto US$25.0 M worth of its common- shares to the LPC over its 30-month term. Oncolytics Biotech, Inc. (USA)(NASDAQ:ONCY) shares moved up 5.26% in last trading session and was closed at $1.80, while trading in range of $ 1.70 – 1.83. Oncolytics Biotech, Inc. (USA)(NASDAQ:ONCY) year to date (YTD) performance is 16.13%.
Myriad Genetics, Inc. (Nasdaq:MYGN) announced that Tesaro, Inc. (Nasdaq: TSRO) will use Myriad’s novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed. TESARO Inc (NASDAQ:TSRO) weekly performance is -14.94%. On last trading day company shares ended up $30.62. TESARO Inc (NASDAQ:TSRO) distance from 50-day simple moving average (SMA50) is -5.51%. Analysts mean target price for the company is $50.83.
Leave a Reply